Cargando…

Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma

BACKGROUND: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Man Hung, Mejlænder-Andersen, Eline, Manueldas, Sophia, El Jellas, Khadija, Steine, Solrun J., Tjensvoll, Kjersti, Sætran, Hege Aase, Knappskog, Stian, Hoem, Dag, Nordgård, Oddmund, Hovland, Randi, Molven, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321709/
https://www.ncbi.nlm.nih.gov/pubmed/30611220
http://dx.doi.org/10.1186/s12885-018-5195-7
_version_ 1783385506672803840
author Choi, Man Hung
Mejlænder-Andersen, Eline
Manueldas, Sophia
El Jellas, Khadija
Steine, Solrun J.
Tjensvoll, Kjersti
Sætran, Hege Aase
Knappskog, Stian
Hoem, Dag
Nordgård, Oddmund
Hovland, Randi
Molven, Anders
author_facet Choi, Man Hung
Mejlænder-Andersen, Eline
Manueldas, Sophia
El Jellas, Khadija
Steine, Solrun J.
Tjensvoll, Kjersti
Sætran, Hege Aase
Knappskog, Stian
Hoem, Dag
Nordgård, Oddmund
Hovland, Randi
Molven, Anders
author_sort Choi, Man Hung
collection PubMed
description BACKGROUND: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the primary tumor and pancreatic juice from the same patient. METHODS: Amplicon-based targeted deep sequencing was performed on samples from 21 patients with pancreatic ductal adenocarcinoma (PDAC) who had undergone Whipple’s operation. Mutation profiles were determined in formalin-fixed sections of the primary tumor and in pancreatic juice sampled from the main pancreatic duct during surgery. RESULTS: Using a cut-off of 3% for variant allele frequency, KRAS mutations were detected in 20/21 primary tumors (95%) and in 15/21 (71%) juice samples. When also considering low-frequency variants, KRAS mutations were found in 20/21 juice samples. Most juice samples exhibited multiple KRAS variants not seen in the primary tumor, and only in 11 cases (52%) did the most abundant variant of the juice correspond to the KRAS mutation detected in the tumor. TP53 mutations were found in 16 tumors (76%) and six juice samples (29%). Among the positive juice samples, only one exhibited more than a single TP53 mutation. Detection of both KRAS and TP53 mutations was fully concordant in the primary tumor and juice sample in 7/21 cases (33%). CONCLUSIONS: Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and possibly reflecting precancerous lesions in other regions of the pancreas. The inclusion of TP53 mutation detection and additional markers must therefore be considered for fully exploiting the clinical potential of pancreatic juice samples in early cancer detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5195-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6321709
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63217092019-01-09 Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma Choi, Man Hung Mejlænder-Andersen, Eline Manueldas, Sophia El Jellas, Khadija Steine, Solrun J. Tjensvoll, Kjersti Sætran, Hege Aase Knappskog, Stian Hoem, Dag Nordgård, Oddmund Hovland, Randi Molven, Anders BMC Cancer Research Article BACKGROUND: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the primary tumor and pancreatic juice from the same patient. METHODS: Amplicon-based targeted deep sequencing was performed on samples from 21 patients with pancreatic ductal adenocarcinoma (PDAC) who had undergone Whipple’s operation. Mutation profiles were determined in formalin-fixed sections of the primary tumor and in pancreatic juice sampled from the main pancreatic duct during surgery. RESULTS: Using a cut-off of 3% for variant allele frequency, KRAS mutations were detected in 20/21 primary tumors (95%) and in 15/21 (71%) juice samples. When also considering low-frequency variants, KRAS mutations were found in 20/21 juice samples. Most juice samples exhibited multiple KRAS variants not seen in the primary tumor, and only in 11 cases (52%) did the most abundant variant of the juice correspond to the KRAS mutation detected in the tumor. TP53 mutations were found in 16 tumors (76%) and six juice samples (29%). Among the positive juice samples, only one exhibited more than a single TP53 mutation. Detection of both KRAS and TP53 mutations was fully concordant in the primary tumor and juice sample in 7/21 cases (33%). CONCLUSIONS: Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and possibly reflecting precancerous lesions in other regions of the pancreas. The inclusion of TP53 mutation detection and additional markers must therefore be considered for fully exploiting the clinical potential of pancreatic juice samples in early cancer detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5195-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-05 /pmc/articles/PMC6321709/ /pubmed/30611220 http://dx.doi.org/10.1186/s12885-018-5195-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Choi, Man Hung
Mejlænder-Andersen, Eline
Manueldas, Sophia
El Jellas, Khadija
Steine, Solrun J.
Tjensvoll, Kjersti
Sætran, Hege Aase
Knappskog, Stian
Hoem, Dag
Nordgård, Oddmund
Hovland, Randi
Molven, Anders
Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
title Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
title_full Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
title_fullStr Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
title_full_unstemmed Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
title_short Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
title_sort mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321709/
https://www.ncbi.nlm.nih.gov/pubmed/30611220
http://dx.doi.org/10.1186/s12885-018-5195-7
work_keys_str_mv AT choimanhung mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT mejlænderanderseneline mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT manueldassophia mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT eljellaskhadija mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT steinesolrunj mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT tjensvollkjersti mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT sætranhegeaase mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT knappskogstian mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT hoemdag mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT nordgardoddmund mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT hovlandrandi mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma
AT molvenanders mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma